About EYLEA Results of phase 3 Eylea
clinical trials1
SEE THE DATA

A legacy of clinical experience

btn btn

9 years of extensive real-world experience1

btn btn

≈13 million doses administered to >1 million eyes since launch (and counting)9

btn btn

8 phase 3 clinical trials, including >3000 EYLEA-treated patients across all approved indications: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)1,9

EYLEA® (aflibercept) pre-filled syringe and packaging. EYLEA® (aflibercept) pre-filled syringe and packaging.
ACCESSING EYLEA Comprehensive support for you and your patients Find support
Patient Support Patient Support

We’re committed to helping ensure your eligible patients have access to EYLEA.

Reimbursement Reimbursement

Get information about navigating the
reimbursement process. Find
enrollment forms, learn about PA
assistance, and more.

Product Support Product Support

Find complete product support—guiding you through orders, returns, and more.

RESOURCES Do you and your patients
need more information
about EYLEA?
See Resources

Find videos, pamphlets, approval letters, and more

    AMD, Age-Related Macular Degeneration; anti-VEGF, anti–vascular endothelial growth factor; DME, Diabetic Macular Edema; DR, Diabetic Retinopathy; MEfRVO, Macular Edema following Retinal Vein Occlusion (includes Branch Retinal Vein Occlusion [BRVO] and Central Retinal Vein Occlusion [CRVO]).
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S.
    Prescribing Information. Regeneron
    Pharmaceuticals, Inc. August 2019.
  2. Heier JS, Brown DM, Chong V, et al; for the
    VIEW 1 and VIEW 2 Study Groups. Intravitreal
    aflibercept (VEGF Trap-Eye) in wet age-
    related macular degeneration. Ophthalmology.
    2012;119(12):2537-2548. doi:10.1016/
    j.ophtha.2012.09.006
  3. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et
    al. Intravitreal aflibercept injection for
    neovascular age-related macular
    degeneration: ninety-six-week results of the
    VIEW studies. Ophthalmology.
    2014;121(1):193-201. doi:10.1016/
    j.ophtha.2013.08.011
  4. Brown DM, Schmidt-Erfurth U, Do DV, et al.
    Intravitreal aflibercept for diabetic macular
    edema: 100-week results from the VISTA and
    VIVID studies. Ophthalmology.
    2015;122(10):2044-2052. doi:10.1016/
    j.ophtha.2015.06.017
  5. Campochiaro PA, Clark WL, Boyer DS, et al.
    Intravitreal aflibercept for macular edema
    following branch retinal vein occlusion: the
    24-week results of the VIBRANT study.
    Ophthalmology. 2015;122(3):538-544.
    doi:10.1016/j.ophtha.2014.08.031
  6. Boyer D, Heier J, Brown DM, et al. Vascular
    endothelial growth factor Trap-Eye for
    macular edema secondary to central retinal
    vein occlusion: six-month results of the phase
    3 COPERNICUS study. Ophthalmology.
    2012;119(5):1024-1032. doi:10.1016/
    j.ophtha.2012.01.042
  7. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-
    Eye for macular oedema secondary to central
    retinal vein occlusion: 6-month results of the
    phase III GALILEO study. Br J Ophthalmol.
    2013;97(3):278-284. doi:10.1136/
    bjophthalmol-2012-301504
  8. Wykoff CC. Intravitreal Aflibercept for
    Moderately Severe to Severe Non-Proliferative
    Diabetic Retinopathy (NPDR): 2-Year Outcomes
    of the Phase 3 PANORAMA Study. Data
    presented at: Angiogenesis, Exudation and
    Degeneration Annual Meeting; February 8,
    2020; Miami, FL.
  9. Data on file. Regeneron Pharmaceuticals, Inc.